Close Menu

NEW YORK (GenomeWeb News) – Companion diagnostics and biomarker development company Flagship Biosciences announced late on Monday its purchase of immunohistochemistry and immunofluorescence firm IHCtech for an undisclosed amount.

In a statement, Flagship President David Young said the deal provides his company "the opportunity to internally evaluate tissue staining and implement new processes that better equip immunohistochemistry operations for use in quantitative pathology with whole slide imaging analysis."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.